Zahlen für Q3/22
- kein Umsatz
- Verlust 40 Mio. $
- Cash 203 Mio. $
- MK 64 Mio. $
- Cash runway into 2025 prioritizing Ixo-vec clinical development in wet age-related macular degeneration (wet AMD)
investors.adverum.com/news/news-details/...sults/default.aspx